The role of pharmacotherapy in the management of self-regulation difficulties in young children

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 18, Issue 2, 2009, Pages 150-159

  Reebye, Pratibha N ^a   Elbe, Dean ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Pharmacotherapy; Self regulation; Young children

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; ATOMOXETINE; BENZODIAZEPINE; CAFFEINE; CARBAMAZEPINE; CHLORPROMAZINE; CLONIDINE; DESIPRAMINE; FISH OIL; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; GINKGO BILOBA EXTRACT; GUANFACINE; HALOPERIDOL; LORAZEPAM; MELATONIN; METHYLPHENIDATE; MOOD STABILIZER; NALTREXONE; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ABDOMINAL PAIN; AGGRESSION; AGITATION; ANTICHOLINERGIC SYNDROME; ANXIETY DISORDER; ATAXIA; ATTENTION DEFICIT DISORDER; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; BRAIN DAMAGE; CHILD; CHILD BEHAVIOR; CHILD GROWTH; CHILD PSYCHIATRY; CLINICAL PRACTICE; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DOWN SYNDROME; DROWSINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSTONIA; EMOTIONAL DISORDER; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FEVER; GROWTH RETARDATION; HUMAN; HYPERSALIVATION; HYPOTENSION; IMPULSIVENESS; INSOMNIA; INTELLECTUAL IMPAIRMENT; IRRITABILITY; LIVER TOXICITY; LOW DRUG DOSE; MENTAL DEFICIENCY; METABOLIC DISORDER; MOOD DISORDER; MUSCLE STIFFNESS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; OBESITY; OBSESSIVE COMPULSIVE DISORDER; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PSYCHOPHARMACOLOGY; REBOUND; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SEPARATION ANXIETY; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STOMACH PAIN; SUDDEN DEATH; TARDIVE DYSKINESIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIVID DREAM; VOMITING; WEIGHT GAIN;

EID: 70349174860     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Abikoff, H. B., Vitiello, B., Riddle, M. A., Cunningham, C., Greenhill, L. L., Swanson, J. M. et al. (2007). Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/ Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 17, 581-592.
2. Bailey, B., Letarte, A., & Abran, M. C. (2005). Methylphenidate unintentional ingestion in preschool children. Therapeutic Drug Monitoring, 27, 284-286.
3. Bezchlibnyk-Butler, K. Z. & Virani, A. S. (2007). Clinical Handbook of Psychotropic Drugs for Children and Adolescents. Anxiolytic Agents (pp 169-187). Cambridge, MA: Hogrefe & Huber.
4. Calkins, S. D. & Fox, N. A. (2002). Self-regulatory processes in early personality development: a multi-level approach to the study of childhood social withdrawal and aggression. Developmental Psychopathology, 14, 477-498.
5. Calkins, S. D., Dedmon, S. E. (2000). Physiological and behavioural regulation in two year old children with aggressive/destructive behaviour problems. Journal of Abnormal Child Psychology, 2, 103-118.
6. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacists Association; 2008.
7. Carr, R., Wasdell, M. B., Hamilton, D., Weiss, M. D., Freeman, R. D., Tai, J. et al. (2007). Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. Journal of Pineal Research, 43, 351-359.
8. Cazzullo, A. G., Musetti, M. C., Musetti, L., Bajo, S., Sacerdote, P., Panerai, A (1999). Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. European Neuropsychopharmacology, 9, 361-6.
9. Chertin, B., Koulikov, D., Abu-Arafeh, W., Mor, Y., Shenfeld, O. Z., & Farkas, A. (2007). Treatment of nocturnal enuresis in children with attention deficit hyperactivity disorder. Journal of Urology, 178, 1744-1747.
10. Cicchetti, D., Toth, S. L. (1991). Rochester Symposium on Developmental Psychopathology: Internalizing and externalizing expressions of dysfunction. Hillsdale, N.J.: Lawrence Erlbaum Associates.
11. Clark, D. B., Birmaher, B., Axelson, D., Monk, K., Kalas, C., Ehmann, M. et al. (2005). Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 1263-1270.
12. Cole, P. M., Martin, S. E., & Dennis, T. A. (2004). Emotion regulation as a scientific construct: methodological challenges and directions for child development research. Child Development, 75, 317-333.
13. Correll, C. U. (2005). Metabolic side effects of Second - generation antipsychotics in Children and Adolescents: A Different story? Journal of Clinical Psychiatry, 66, 1331-1332.
14. Daviss, W. B., Patel, N. C., Robb, A. S., McDermott, M. P., Bukstein, O. G., Pelham, W. E., Jr. et al. (2008). Clonidine for attention-deficit/ hyperactivity disorder: II. ECG changes and adverse events analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 47, 189-198.
15. Dieleman, G. C. & Ferdinand, R. F. (2008). Pharmacotherapy for social phobia, generalised anxiety disorder and separation anxiety disorder in children and adolescents: an overview. Tijdschrift voor Psychiatrie, 50, 43-53.
16. Eisenberg, N., Cumberland, A., Spinrad, T. L., Fabes, R. A., Shepard, S. A., Reiser, M. et al. (2001). The relations of regulation and emotionality to children's externalizing and internalizing problem behavior. Child Development, 72, 1112-1134.
17. Eisenberg N., Spinrad, T. L., & Smith, C. L. (2004). Emotion related Regulation: Its Conceptualization, Relations to Social Functioning, and Socialization. In Philippot, P. & Feldman R. S. (.Eds), The Regulation of Emotion. (pp. 281). Hillsdale, N.J.: Lawrence Erlbaum Associates.
18. Feldman, R., Greenbaum, C. W., & Yirmiya, N. (1999). Mother-infant affect synchrony as an antecedent of the emergence of self-control. Developmental. Psychology, 35, 223-231.
19. Findling, R. L. (2008). Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. Journal of Clinical Psychiatry, 69 Suppl 4, 9-14.
20. Fox, N. A. & Calkins, S. D. (2003). The development of self-control of emotion. Intrinsic and extrinsic influences. Motivation and Emotion, 27, 7-26.
21. Fox, N. A., Henderson, H. A., Rubin, K. H., Calkins, S. D., & Schmidt, L. A. (2001). Continuity and discontinuity of behavioral inhibition and exuberance: psychophysiological and behavioral influences across the first four years of life. Child Development, 72, 1-21.
22. Fraguas, D., Merchan-Naranjo, J., Laita, P., Parellada, M., Moreno, D., Ruiz-Sancho, A. et al. (2008). Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. Journal of Clinical Psychiatry, 69, 1166-1175.
23. Ghuman, J. K., Riddle, M. A., Vitiello, B., Greenhill, L. L., Chuang, S. Z., Wigal, S. B. et al. (2007). Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 17, 563-580.
24. Gleason, M. M., Egger, H. L., Emslie, G. J., Greenhill, L. L., Kowatch, R. A., Lieberman, A. F. et al. (2007). Psychopharmacological treatment for very young children: contexts and guidelines. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1532-1572.
25. Greenhill, L., Kollins, S., Abikoff, H., McCracken, J., Riddle, M., Swanson, J. et al. (2006). Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1284-1293.
26. Greenhill, L. L., Vitiello, B., Abikoff, H., Levine, J., March, J. S., Riddle, M. A. et al. (2003). Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 651-655.
27. Harmon, R. J. & Riggs, P. D. (1996). Clonidine for post-traumatic stress disorder in preschool children. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1247-1249.
28. Hazell, P. L. & Stuart, J. E. (2003). A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 886-894.
29. Jan, J. E. & Espezel, H. (1995) Melatonin treatment of chronic sleep disorders. Developmental Medicine & Child Neurology, 37, 279-280.
30. Jan, J. E. & O'Donnell, M. E. (1996). Use of melatonin in the treatment of paediatric sleep disorders. Journal of Pineal Research, 21, 193-199.
31. Keenan, K. (2000). Emotion regulation as a risk factor for child psychopathology. Clinical Psychology: Science and Practice, 7, 418-434.
32. Klein, D. J., Cottingham, E. M., Sorter, M., Barton, B. A., & Morrison, J. A. (2006). A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. American Journal of Psychiatry, 163, 2072-2079.
33. Klein, R. G., Landa, B., Mattes, J. A., & Klein, D. F. (1988). Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Archives of General Psychiatry, 45, 1127-1130.
34. Klein, R. G. & Mannuzza, S. (1988). Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height. Archives of General Psychiatry, 45, 1131-1134.
35. Kochanska, G., Murray, K. T., & Harlan, E. T. (2000). Effortful control in early childhood: continuity and change, antecedents, and implications for social development. Developmental Psychology, 36, 220-232.
36. Kratochvil, C. J., Greenhill, L. L., March, J. S., Burke, W. J., & Vaughan, B. S. (2004). The role of stimulants in the treatment of preschool children with attention-deficit hyperactivity disorder. CNS Drugs, 18, 957-966.
37. Kring, A. M. & Werner, K. H. (2004). Emotion regulation in psychopathology. In P. Philippot & R. S. Feldman (Eds). The Regulation of Emotion (pp. 359-385). Hillsdale, NJ: Lawrence Erlbaum Associates.
38. Kutcher, S. P. (1997). Child and Adolescent Psychopharmacology. Philadelphia, PA: W.B. Saunders Company.
39. Lee, B. J. (1997). Clinical experience with guanfacine in 2- and 3-year-old children with Attention Deficit Hyperactivity Disorder. Infant Mental Health Journal, 18, 300-305.
40. Luby, J. L., Heffelfinger, A. K., Mrakotsky, C., Hessler, M. J., Brown, K. M., & Hildebrandt, T. (2002). Preschool major depressive disorder: preliminary validation for developmentally modified DSM-IV criteria. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 928-937.
41. Luby, J. L., Mrakotsky, C., Heffelfinger, A., Brown, K., Hessler, M., & Spitznagel, E. (2003). Modification of DSM-IV criteria for depressed preschool children. American Journal of Psychiatry, 160, 1169-1172.
42. Luby, J. L., Mrakotsky, C., Heffelfinger, A., Brown, K., & Spitznagel, E. (2004). Characteristics of depressed preschoolers with and without anhedonia: evidence for a melancholic depressive subtype in young children. American Journal of Psychiatry, 161, 1998-2004.
43. Maloney, M. J. & Schwam, J. S. (1995). Clonidine and sudden death. Pediatrics, 96, 1176-1177.
44. MTA Cooperative Group (2004). National Institute of Mental Health multimodal treatment study of ADHD follow up: Changes in the effectiveness and growth after the end of treatment. Pediatrics, 113, 762-769.
45. Oberlander, T. F., Misri, S., Fitzgerald, C. E., Kostaras, X., Rurak, D., & Riggs, W. (2004). Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Journal of Clinical Psychiatry, 65, 230-237.
46. Parikh, M. S., Kolevzon, A., & Hollander, E. (2008) Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. Journal of Child and Adolescent Psychopharmacology, 18, 157-78.
47. Physicians' Desk Reference (ed. 62). Medical Economics Data Production Company, Montvale, New Jersey; 2008.
48. Posner, M. I. & Rothbart, M. K. (1998). Attention, self-regulation and consciousness. Philos. Trans. R. Soc. Lond. Biol. Sci., 353, 1915-1927.
49. Poulton, A. & Cowell, C. T. (2003). Slowing of growth in height and weight on stimulants: a characteristic pattern. Journal of Paediatrics & Child Health, 39, 180-185.
50. Research Unit on Pediatric Psychopharmacology Anxiety Study Group (2001). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. New England Journal of Medicine, 344, 1279-1285.
51. Riddle, M. A., Geller, B., & Ryan, N. (1993). Another sudden death in a child treated with desipramine. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 792-797.
52. Riddle, M. A., Nelson, J. C., Kleinman, C. S., Rasmusson, A., Leckman, J. F., King, R. A., et al. (1991). Sudden death in children receiving Norpramin: a review of three reported cases and commentary. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 104-108.
53. Ross, B. M., Seguin, J., & Sieswerda, L. E. (2007). Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids in Health and Disease, 6, 21.
54. Rubin, K. H. & Asendorpf, J. B. (1993). Social withdrawal, inhibition, and shyness in childhood. Hillsdale, NJ: Lawrence Erlbaum Associates.
55. Ruff, H. A. & Rothbart, M.K. (1996). Looking and Visual Attention: Overview and Developmental Framework. In Attention In Early Development: Themes and Variations (pp. 34-56). New York, N.Y.: Oxford University Press.
56. Sandson, N. (2005). Drug-drug interactions: the silent epidemic. Psychiatric Services, 56, 22-24.
57. Sandson, N. B., Armstrong, S. C., & Cozza, K. L. (2005). An overview of psychotropic drug-drug interactions. Psychosomatics, 46, 464-494.
58. Schore, A. N. (1991). The experience-dependent maturation of a regulatory system in the orbital prefrontal cortex and the origin of developmental psychopathology. Development and Psychopathology, 8, 59-87.
59. Sethi, A., Mischel, W., Aber, J. L., Shoda, Y., & Rodriguez, M. L. (2000). The role of strategic attention deployment in development of self-regulation: predicting preschoolers' delay of gratification from mother-toddler interactions. Developmental Psychology, 36, 767-777.
60. Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I. et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634-e641.
61. Silva, R. R., Campbell, M., Golden, R. R., Small, A. M., Pataki, C. S., & Rosenberg, C. R. (1992). Side effects associated with lithium and placebo administration in aggressive children. Psychopharmacology Bulletin, 28, 319-326.
62. Silva, R. R. (2005). Recent pharmacologic updates. Journal of Child and Adolescent Psychopharmacology, 15, 715-716.
63. Staller, J. A. (2007). Psychopharmacologic treatment of aggressive preschoolers: a chart review. Progress in Neuropsychopharmacology and Biological Psychiatry, 31, 131-135.
64. Swanson, J., Greenhill, L., Wigal, T., Kollins, S., Stehli, A., Davies, M., et al. (2006). Stimulant-related reductions of growth rates in the PATS. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1304-1313.
65. Swanson, J. M., Flockhart, D., Udrea, D., Cantwell, D., Connor, D., Williams, L. (1995). Clonidine and the treatment of ADHD: Questions about safety and efficacy. Journal of Child and Adolescent Psychopharmacology, 5, 301-304.
66. Wilens, T. E., Biederman, J., Brown, S., Monuteaux, M., Prince, J., & Spencer, T. J. (2002). Patterns of psychopathology and dysfunction in clinically referred preschoolers. Journal of Developmental Behavior and Pediatrics, 23, S31-S36.
67. Wolf, S. M., Shinnar, S., Kang, H., Gil, K. B., & Moshe, S. L. (1995). Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia, 36, 1203-1205.
68. Wolraich, M. L. (2003). Annotation: The use of psychotropic medications in children: an American view. Journal of Child Psychology and Psychiatry, 44, 159-168.
69. Wozniak, J. (2005). Recognizing and managing bipolar disorder in children. Journal of Clinical Psychiatry, 66 Suppl 1, 18-23.
70. Zito, J. M., Safer, D. J., dosReis, S., Gardner, J. F., Boles, M., & Lynch, F. (2000). Trends in the prescribing of psychotropic medications to preschoolers. Journal of the American Medical Association, 283, 1025-1030.
71. Zito, J. M., Safer, D. J., Valluri, S., Gardner, J. F., Korelitz, J. J., & Mattison, D. R. (2007). Psychotherapeutic medication prevalence in Medicaid-insured pre-schoolers. Journal of Child and Adolescent Psychopharmacology, 17, 195-203.